A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled, Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effe
Administered By
Awarded By
Contributors
- Beerman, Rebecca Clinical Data Manager
- Montefiori, David Charles Principal Investigator
- Sarzotti-Kelsoe, Marcella Director
- Shen, Xiaoying Co Investigator
Start/End
- June 1, 2021 - May 31, 2024